Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Unlocking new horizons: advances in treating IDH-mutant, 1p/19q-codeleted oligodendrogliomas

31 May 2025

Abstract excerpt

Oligodendrogliomas are a distinct subtype of diffuse gliomas characterized by IDH mutations and 1p/19q codeletion, classified as grade 2 or 3 based on histological features. This review examines current advancements in the diagnosis, treatment, and prognosis of oligodendrogliomas, with an emphasis on personalized approaches driven by molecular insights. Surgery remains the cornerstone of treatment, aiming for...

Topics

Join the communities discussing this publication.

Glioma Diagnosis and Treatment
Neuroblastoma Research and Treatments
Protein Degradation and Inhibitors

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 40448901
DOI: 10.1007/s12672-025-02815-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Unlocking new horizons: advances in treating IDH-mutant, 1p/19q-codeleted oligodendrogliomasPMID 40448901Read ↗

Oligodendroglioma: pathology, molecular mechanisms and markersSemantic proximity Read ↗

Oligodendroglioma, IDH-mutant and 1p/19q-codeleted-prognostic factors, standard of care and chemotherapy, and future perspectives with neoadjuvant strategy.Semantic proximity Read ↗

[Oligodendroglioma, IDH Mutation and 1p/19q Codeletion].Semantic proximity Read ↗

Role of Molecular Pathology in the Treatment of Anaplastic Gliomas and Glioblastomas.Semantic proximity Read ↗

A review of adult-type diffuse gliomas in the WHO CNS5 classification with special reference to Astrocytoma, IDH-mutant and Oligodendroglioma, IDH-mutant and 1p/19q codeleted.Semantic proximity Read ↗

Low-grade IDH -mutant gliomas: from standard post-surgical treatments to novel IDH inhibitorsSemantic proximity Read ↗

Advances in the treatment of IDH-mutant gliomas.Semantic proximity Read ↗

IDH-mutant diffuse gliomas: tips and tricks in the era of genomic tumor classification.Semantic proximity Read ↗

Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.Semantic proximity Read ↗

Challenges in the Diagnosis and Management of Low-Grade Gliomas.Semantic proximity Read ↗

The Role of Molecular Diagnostics in the Management of Patients with Gliomas.Semantic proximity Read ↗

Advances in translational research in neuro-oncology.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.